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The pro-inflammatory cytokines interleukin 1 (IL-1) and 6 (IL-6) are crucially involved in the
regulation of a multitude of physiological processes, in particular coordinating the immune
response upon bacterial infection and tissue injury. Both interleukins induce complex signalling
cascades and trigger the production of mitogenic, pro-proliferative, anti-apoptotic, chemotactic,
and pro-angiogenic factors thereby affecting the delicate balance between regeneration vs. invasive
growth, tumourigenesis and metastasis. Moreover, several links to insulin resistance have been
found within their associated signalling networks. Focusing on this from a systems biology
perspective, we introduce comprehensive large-scale network models of IL-1 and IL-6 signalling
which are based on a logical modelling approach and reflect the current biological knowledge.
Theoretical network analysis enabled us to uncover general topological features and to make
testable predictions on the stimulus-response behaviour of the networks. In this context,
non-intuitive network-wide species dependencies as well as structures of regulatory feedback
and feed-forward mechanisms could be characterised. By integrating high-throughput
phosphoproteomic data from primary human hepatocytes we optimised the model structures to
obtain models with high prediction accuracy for hepatocytes. Our model-based data analysis, for
instance, suggested model modifications regarding (i) Akt contribution to IL-1-stimulated p38
MAPK activation and (ii) insignificant p38 MAPK activation in response to IL-6. In light of the
presented results and in conjunction with the detailed model documentations, both models hold
great potential for theoretical studies and practical applications.
Introduction
The two pleiotropic factors of inflammatory response, inter-
leukin 1 (IL-1) and 6 (IL-6) are induced and expressed by a
wide range of cell types, including monocytes, endothelial
cells, and fibroblasts in response to, for example, endotoxic
stimulus exposure or stimulation with initiators of sequential
inflammatory cytokine release such as tumour necrosis factor
(TNF) and interferon (IFN) isoforms.1–5 Both interleukins
control hepatic acute-phase protein (APP) secretion6–10 during
innate immune response upon bacterial infection and tissue
injury, facilitating regeneration and wound healing. The
IL-1-induced release of potent immune attractors and/or chemo-
kines (e.g. CCL2 (MCP1), IL-8)11,12 triggers transmigration of
immunocompetent cells (e.g. activated macrophages, granulo-
cytes) to sites of inflammation. Moreover, IL-1 and IL-6 may
effect the delicate balance between regeneration vs. invasive
growth, tumourigenesis, and metastasis13,14 in conjunction with
hepatitis, ischemia, and cirrhosis15,16 by up-regulating the produc-
tion of mitogenic, pro-proliferative, anti-apoptotic, chemotactic,
and pro-angiogenic growth factors like HGF.17–19 Apart from
that, JNK and IKKb activation by IL-120–22 as well as SOCS
expression23,24 or SHP2 phosphatase25 and ERK kinase26 activi-
ties induced by IL-6 stimulation link these ligands to insulin
desensitisation and subsequent insulin resistance.
In this work, we introduce large-scale Boolean network models
of IL-1 and IL-6 signalling manually compiled from literature
and database knowledge. Comprehensive pathway diagrams
such as the IL-1 signalling map by Kracht et al.27,28 served as
starting points and valuable information sources for model
construction. The fact that both interleukins share common
signalling cascades and effectors (e.g. PI3K/Akt, MEK1/ERK,
SOCS1/3) prompted us to study their associated signal transduc-
tion networks in parallel. A qualitative (parameter-free) model-
ling approach previously applied to T cell receptor29 and EGFR/
ErbB signalling30 was adopted, providing the mathematical
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framework for the two ‘‘master models’’ represented here.
Subsequent network analysis aimed at the following three
major objectives: (i) examination of general IL-1/IL-6 network
properties, (ii) analysis of crosstalk strategies of both cytokines
as well as their influences on HGF- and insulin-induced
signalling pathways, and (iii) comparison of qualitative model
predictions with phosphoproteomic data from primary human
hepatocytes to delineate hepatocellular specifics within IL-1
and IL-6 signal propagation.
Each model comprises more than 70 nodes (e.g. scaffold
proteins, kinases, transcription factors) and 80 interactions.
The high number of species and reactions along with insuffi-
cient information on reaction kinetics and protein concentra-
tions impedes quantitative and time-resolved descriptions of
large-scale signalling networks by ordinary differential equations
(ODEs). Consequently, our models focus on the wiring diagrams
of as well as Boolean relationships in IL-1 and IL-6 signalling.
This representation not only suits to uncover major players and
interactions but also to reveal network-wide interdependencies.
Furthermore, it serves as an ‘‘executable pathway map’’ to
study stimulus-response (input–output) behaviours or to com-
pute minimal intervention sets (MIS)31 that enforce a predefined
cellular response.
The literature-derived network models presented here
capture the current state of biological knowledge concerning
IL-1 and IL-6 signalling pathways to an extent that has not been
described before, particularly regarding IL-6. We validated the
network structures by means of high-throughput experimental
data from primary human hepatocytes exposed to specific
ligand/intracellular kinase inhibitor combinations.32 Detected
discrepancies between data and ‘‘master model’’ predictions
were used for topological optimisation to obtain specific
models reflecting the hepatocellular phenotype.
Results
As a first step, we reconstructed two Boolean ‘‘master models’’
for IL-1 (model M1; Fig. 1) and IL-6 (model M2; Fig. 2) by
merging biological knowledge from various cell types as
provided by databases and scientific literature (see supplemen-
tary model documentations, ESIw). Both models are represen-
ted as logical interaction hypergraphs (LIHs, cf. ‘‘Methods/
Model set-up’’) allowing efficient visualisation and storage
of logical relationships.31 Excluding dummy variables and
reservoirs (cf. ‘‘Methods’’), M1 (M2) contains 97 (75) nodes
or species and 113 (84) interactions. 17 (15) nodes are inputs
to the model not regulated within the scope of the network
(e.g. ligands, receptor subunits, and regulatory phosphatases)
and therefore predefined by default values (see Tables S3.1
and S4.1, ESIw) during simulations. 12 (12) nodes represent
outputs, mainly depicting APPs, cytokines, and transcription
factors. Each interaction was additionally characterised by a
confidence level given in Tables S3.2 and S4.2 (ESIw) and
colour-coded in Fig. 1 and 2, denoting whether an effect has
already been shown (with respect to cited sources) for hepato-
cytes or for other cell types stimulated with IL-1 or IL-6. 11 (8)
interactions were integrated by means of incomplete truth table
(ITT) operators as physiological evidence for a clear distinc-
tion between AND or OR connections could not be derived
from the literature. Furthermore, we classified 21 (16) inter-
actions as secondary or ‘‘post-initial’’ events (e.g. interactions
closing feedback loops), therefore setting their respective
relevance parameter to t = 2 (see also ‘‘Methods/Model set-up’’).
The logical analysis represented here principally focused on
initial signal propagation scenarios and how they result in
transcriptional activity and/or gene expression. ‘‘t = 2’’
interactions indicate effects that do not influence the initial
systemic behaviour but may contribute to system dynamics
at later time points. Nevertheless, we kept those events in the
model, e.g. for studying the feedback structure of the net-
works, whereas excluded them when doing logical simulations.
Importantly, as described by Klamt et al.,30,31 a Boolean
model can be analysed either directly by using its logical
description or with respect to its underlying interaction graph
(IG), comprising no explicit logical statements and edges,
hence capturing nothing but influences. IGs are thus simpler
representations of signalling topologies, however, they facilitate
studies on important topological properties such as feedback
loops or interdependencies. Deriving the associated IG from a
logical model is trivial as long as the latter is given in LIH
representation (cf. ‘‘Methods’’). Accordingly, both IG and LIH
representation are used for model and data analysis described
below.
Model set-up and visualisation was realised with ProMoT,33–35
whereas qualitative analyses were performed using CellNet-
Analyzer (CNA)36,37 (see also ‘‘Methods/Model set-up’’).
Topological features revealed by interaction graph analysis
In order to analyse intrinsic topological properties (e.g. feed-
back loops and global species dependencies) independently of
any Boolean description, we first studied the directed inter-
action graphs31 uniquely underlying the logical modelsM1 (IL-1)
and M2 (IL-6) henceforth referred to as IG1 and IG2 res-
pectively (see also ‘‘Methods’’). Generally, IGs solely cover
pairwise positive or negative effects between species within a
network, irrespectively of the deterministic logic functions
chosen. Feedback loops (FLs) essentially affect system dyna-
mics, on the one hand amplifying input signals and inducing
multistationarity (both being relevant for cellular differen-
tiation and decision processes) if positive, whereas ensuring
cellular homoeostasis or re-sensitisation and possibly being
accompanied by oscillatory behaviour if negative.38–41 The
interaction graph associated to IL-1 (IL-6) signalling com-
prises 16515 (350) feedback loops, thereof 49.9% (39.1%)
negative. Fig. S1 (S2; see ESIw) illustrates the individual FL
participation of species involved in IL-1 (IL-6) signalling,
revealing, for instance, the Y-phosphorylated IL-6 receptor
complex, membrane-bound and phosphorylated Gab1 adaptor
proteins, and phosphatase SHP2 as ‘‘IL-6 feedback protagonists’’.
With respect to IL-1 signalling, more than 80% of detected
FLs require the involvement of mitogen-activated kinases
TAK1, MEKK3, and p38, phosphatase MKP1, and IL-1
receptor antagonists. Negative feedback loops within signal-
ling networks are typically composed of a forward path and
a feedback (either a single edge or a path). Referring to our
models and as delineated subsequently, the former is in all cases
















































































This journal is c The Royal Society of Chemistry 2011 Mol. BioSyst., 2011, 7, 3253–3270 3255
negative feedbacks are: (i) activation of inhibitory phospha-
tases (IL-1: MKP1 vs. IL-6: SHP2), (ii) activation of kinases
(IL-1: p38/MK2) S/T-phosphorylating and thereby negatively
regulating essential scaffold proteins (IL-1: Hsp27, TAB) and
receptor subunits (IL-6: gp130), (iii) up-regulation of inhibi-
tory proteins (IL-1: IkBa vs. IL-6: SOCS1/3) and receptor
antagonists (IL-1: IL-1Ra), (iv) suppression of transcriptio-
nal activities (IL-1: HNF4a), due to elicitor (IL-1: ROS)
‘‘neutralisation’’ by up-regulated corresponding gene products
(IL-1: iNOS), and (v) species degradation (IL-1: TPL2),
inactivating downstream effectors (IL-1: ERK1/2). Most of the
detected positive feedback loops consist of negative forward
paths and subsequent negative feedbacks. Biologically speaking,
activated phosphatases (IL-1: MKP1 vs. IL-6: SHP2) may not
just counteract intracellular inhibitory kinase activities (e.g.
inhibitory p38 activity; cf. (ii)) but also the inhibitory effect of
SOCS1/3 and IL-1Ra, hence positively contributing to receptor
function (Fig. 3A and B).
With respect to IL-6 signalling, PI3K- as well as ERK-
dependent Gab1 membrane translocation and phosphorylation,
Fig. 1 Logical (master) model of IL-1 receptor signalling visualised in ProMoT. Signalling species are symbolised by rectangles and coloured
according to functional involvement: white (dark grey): inhibitory (positive regulatory) inputs/side effectors with default value 0 (1); grey: species/
outputs regulated by up-stream effectors; light green: species acting in both networks (IL-1 and IL-6) revealing systemic crosstalks; dark green:
species depicting links to insulin and HGF signalling. Reservoirs are described by black ellipses. Black arrows (red blunt-ended lines) indicate
activations (inhibitions) with colour shades (grey-black vs. orange-dark red) pointing to confidence levels (0.4–1.0). Secondary events (t = 2) are
displayed by dashed and dotted lines, on the one hand closing feedback loops (dashed), on the other hand seeming of minor initial relevance
(dotted). Diamonds tag ligands and model outputs, whereas circles (squares) indicate logical AND (ITT) operators. Triangles represent OR terms
contributing to complex AND connections. Again, symbol colours of aforementioned operators refer to confidence levels (see above). Dummy
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followed by indirect up-regulation of SHP2 phosphatase activity
and RasGAP release finally boosting ERK activity, uncovered
an additional, classical positive FL mechanism, made up of a
positive forward path and feedback (Fig. 3B, right). Therefore,
the latter strategy may be regarded as ‘‘autonomous’’, given
that no negative feedback is involved and might furthermore
explain the high percentage of positive FLs (60.9%) within the
IL-6 network. Removing the IL-1-regulated species MKP1 and
IL-1Ra (in IG1) or IL-6-induced SHP2 and membrane-bound
phospho-Gab1 (in IG2) would break all positive FLs.
The wealth of signalling species and interactions implies
complex signalling pathways where network-wide inter-
dependencies can hardly be interpreted intuitively. By way of
example, IG1 encompasses 24 372 paths (half of them negative)
leading from ligand IL-1b (input) to IL-8 expression (output).
When focusing on the initial response (i.e. neglecting secondary
‘‘t = 2’’ events), 1386 exclusively positive paths remained. By
checking out the existence of shortest positive or/and negative
directed paths42 between each pair of species, we could indivi-
dually specify the ‘‘triggering’’ effectors as activators or/and
inhibitors (see also ‘‘Methods’’). Revealed information on
network-wide interdependencies were visualised in dependency
matrices.31 The large number of ambivalent dependencies
(owing to nodes that act positively and negatively on certain
down-stream targets; cf. Fig. S3 and S5, ESIw) is significantly
reduced when excluding ‘‘late’’ edges closing feedback loops
(Fig. S4 and S6 (ESIw); dashed ‘‘t = 2’’ interactions in
Fig. 1 and 2 omitted). Residual ambivalences with respect
to IG1 result from: (i) involvement of normal (IL-1RI and
IRAK1) as well as catalytically aberrant enzyme isoforms
(IL-1RII and IRAK1c) in signal propagation, (ii) ABIN2,
alternatively supporting proteasomal TRAF6 and/or NEMO
degradation via A20, (iii) soluble receptor complex compo-
nents (sIL-1RAcP and sIL-1RI/II) blocking activation of
functional (IL-1RI) as well as non-functional (IL-1RII) recep-
tors, (iv) IL-6 and CCL2 up-regulation by activation of
transcription factors AP-1 and NF-kB while simultaneously
inhibiting required basal GSK3 activity, and (v) IL-1b de novo
synthesis by promoting precursor (pro-IL-1b) expression, how-
ever preventing their processing due to inhibition of NALP
inflammasomes. Similar effects in IG2 arise from: (i) SHP2, acting
as an essential adaptor protein but also negative-regulatory
phosphatase and (ii) opposing influences of transcription
factors STAT3 and C/EBPb on cell proliferation.
Studying the input–output behaviour of the logical models
Taking Boolean relationships between converging edges (or
influences) explicitly into account (cf. ‘‘Methods’’ and supple-
mentary model documentations, ESIw) we next focused on predic-
tions of the qualitative network response upon stimulation,
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henceforth referred to as input–output (I/O) behaviour or I/O
response. Computationally, we turned our attention on the
logical steady state (LSS) that follows from the logical model
when prescribing external stimuli and/or systemic perturba-
tions. The LSS and thus I/O response of each species was
calculated by propagating the preassigned binary states of input
variables (ligands and ‘‘side effectors’’) in keeping with specified
logical functions (cf. ‘‘Methods’’ and Klamt et al.30,31). As
already mentioned, we concentrated on the initial cellular
response by excluding secondary ‘‘t = 2’’ events (see dashed/
dotted lines in Fig. 1 and 2). It should furthermore be under-
lined that a node’s LSS computed for a given scenario does not
depict when, but how the former responds to stimulation. The
respective time range required for establishing a certain steady-
state activation pattern may differ among signalling molecules
attributable to intracellular localisation and kinetic parameters.
We started with ‘‘t = 1’’ I/O response simulations in M1,
thereby assuming the presence of at least one IL-1 isoform, the
initial absence of SOCS proteins, and side effector states preset
by default values as indicated in Fig. S7, ESI.w The former
provided a uniquely computable I/O response for all species
except for iNOS (Fig. S7, ESIw). Due to pending scientific
clarification, preventing a clear distinction between AND or
OR connection of respective inputs regarding iNOS regulation,
the latter was modelled using an ITT gate (see ‘‘Methods’’). As
both (positively contributing) inputs differ with respect to their
logical states (HNF4a: 1/on vs. ROS: 0/off by default) a unique
I/O response for iNOS cannot be concluded. In contrast, the
other 10 ITT gates did not impede unique I/O response deter-
mination owing to some ‘‘key’’ upstream effectors (e.g.MYD88,
regulating IRAK1/4 and TAK1, contributing to p38, JNK, and
IKKb/ERK activation) that trigger the concurrent activation of
various signalling molecules via (coherent) feed-forward loops,
reflecting potential redundant pathways within the network.
According to current knowledge,10,11,43 stimulation with IL-1
leads to IL-8 expression as well as SAA and LBP synthesis,
whereas IL-6 and CCL2 release is down-regulated by inhibitory
GSK3 serine phosphorylation. Strikingly, IL-1b secretion is
initially blocked due to inactive caspase-activating complexes,
so called NALP inflammasomes, catalysing the processing of
generated pro-IL-1b precursors but being suppressed by ERK in
response to IL-1 stimulation (Fig. S7, ESIw). Closing a negative
feedback loop by allowing negative-regulatory phosphatase
MKP1 to inhibit causative ERK activity would, however,
theoretically support post-initial IL-1b release, given sufficient
precursor amounts. Similar initial response (t = 1) analysis in
model M2 uncovered the anti-apoptotic and pro-proliferative
effects of IL-6 stimulation, typically associated with pro-
inflammatory cytokines (Fig. S8, ESIw). Assuming that IL-6
does not activate NF-kB, M2 furthermore predicts expression
of acute-phase proteins (e.g. CRP, a2M, gFBG) with exception
of SAA which requires the co-regulation by NF-kB illustrat-
ing potential IL-1/IL-6 crosstalk scenarios (Fig. S8, ESIw).
Moreover, both models provide evidences for links between
inflammation and cellular insulin resistance as well as tissue
regeneration and tumourigenesis, revealing (i) inhibitory IRS1
serine phosphorylation, SHP2-mediated IRS1 inhibition or IR
blocking by SOCS proteins, and (ii) hepatocyte growth factor
(HGF) precursor release and its uPA-regulated processing in
response to IL-1 or/and IL-6 (Fig. S7 and S8, ESIw).
Systemic failure modes might disturb cellular balance and
open the way for chronic inflammation and cell transforma-
tion. Using the concept of minimal intervention sets (MIS)31,37
we exemplarily identified support-minimal sets of species
perturbations (e.g. constitutive activations or knock-outs; see
also ‘‘Methods’’) that would provoke a specific cell response of
interest. Generally, all interactions were incorporated during
MIS computation, ensuring the results to be valid for primary
(t = 1) as well as late or secondary events (t = 2). By
calculating failure modes in M1 that would lead to permanent
IL-8 expression, we could, for instance, identify 56 MISs
enforcing uncontrolled, IL-1-induced or autonomous secretion
of pro-inflammatory IL-8. The latter would require at least three
co-existing (co-occurring) systemic faults within the network, in
any case involving constitutive TAK1 (or MEKK3) and NF-kB
activation. Under normal conditions, this seems very unlikely
given that mentioned effector activities are strictly down-
regulated by internal feedback loops via MK2 and IkBa or,
again pointing to crosstalk effects between IL-1 and IL-6, by
inhibitory SOCS proteins up-regulated by IL-6. MIS studies also
underlined the significance of TAK1 and/or ERK repression
Fig. 3 Basic concepts of positive feedback loops in A: IL-1 and B: IL-6
signalling (schematic). Arrows (blunt-ended lines) indicate activations
(inhibitions). Negative FLs being involved in positive feedback loops
(green line colour) are indicated by dashed lines. Further explanations
are given in the text. See model documentations (Tables S3.1 and S4.1,
ESIw) for full species names. Initial up-stream events associated to
ligand binding are depicted in grey. Green highlighting stresses the
















































































3258 Mol. BioSyst., 2011, 7, 3253–3270 This journal is c The Royal Society of Chemistry 2011
through post-initial feedback mechanisms for IL-1b precursor
processing. Consequently, the coupling of IL-1-stimulated IL-1
de novo expression with negative feedback initiation prevents
autocrine loops while still enabling intercellular signal propaga-
tion. Referring to model M2, MIS computation analogously
revealed that unrestricted cell proliferation and viability in
response to IL-6 is prevented with onset of negative feedback
loops as SOCS expression and SHP2 phosphatase activity
induce cell cycle arrest. Accordingly, inactivation of SOCS
or of SHP2 represent failure modes with respect to permanent
pro-proliferative effects in response to IL-6 stimulation
(i.e. pro-proliferative = 1 for il6  1).
In the light of MIS analysis results, both modelled signalling
networks comprise intrinsic safety mechanisms in the form of
negative feedback loops counteracting potential, e.g. muta-
tional, alterations of effector activities and thereby supporting
systemic robustness.
Hepatocellular validation of the models by integrating
experimental data
Structural network analysis of the models provided insights
into general network properties of IL-1 and IL-6 signalling
and may, e.g. by MIS analysis, offer a platform for studying
pathophysiological behaviours and for identifying potential
drug targets. However, as these ‘‘master’’ models were cons-
tructed from literature data covering several cell types, they
are not implicitly applicable to hepatic conditions. In order to
uncover hepatocellular characteristics, we compared model
predictions to high-throughput experimental data assayed
in primary human hepatocytes for t = 0 and 30 min by
Alexopoulos et al.32 As introduced previously by Samaga
et al.,30 we (i) verified the interaction graphs by contrasting
raw data trends with corresponding dependency matrix predic-
tions and (ii) looked for logical misinterpretations uncovered
by inconsistencies between discretised data and network I/O
responses simulated according to experimental conditions
using the logical models. Detailed descriptions on experimental
data and analysis procedures are given in ‘‘Methods’’ and
Tables S1 and S2 (ESIw); raw data sets and transformed data
applied for IG1/M1 and IG2/M2 validation are visualised in
Fig. S9 and S10, ESI.w
Data analysis by means of interaction graphs
According to procedures explained in ‘‘Methods’’ and using
the readouts shown in Fig. S9.A and S10.A (ESIw) we first
verified the models for IL-1 and IL-6 signalling by focusing on
the underlying interaction graphs IG1 and IG2, respectively.
Given the measurement time range t = 0–30 min primarily
encompassing initial response events, we again excluded
‘‘t=2’’ interactions when calculating corresponding dependency
matrices.
As generally observed, measured trends in species phos-
phorylation in response to certain stimulus scenarios could
largely be mapped by suggested network topologies. Regard-
ing IG1 (IG2), 78% (80%) of calculated species dependencies
agreed with data trends: phosphorylation levels increased in
31% (30%) and decreased in 7% (9%) of the analysed cases
according to predictions; in 40% (41%) of all regarded cases
an effect was neither detected in the measurements nor expec-
ted with respect to pathway topologies. In 10% (9%) of all
cases a significantly increasing or decreasing phosphorylation
level was found experimentally though no effects had been
expected from topology. The remaining 12% (11%) of the
cases (cf. grey entries in Fig. 4 and 5) indicate model-predicted
positive or negative effects not significantly evident in experi-
mental readouts. Those ‘‘grey’’ cases may not represent a
model falsification as perturbation of the start node of a path
does not necessarily induce a significant effect on the activity
of the target (end) species, e.g. owing to saturation effects or
experimental assay detection limits. Fig. 4 and 5 depict consis-
tencies and discrepancies in detail. Conclusions with respect to
model modifications are discussed below.
Data analysis using the logical models
For verifying predictions of the Boolean models regarding the
initial IL-1- or IL-6-induced response behaviour, we converted
continuous raw data, individually assayed for a predefined
treatment scenario, into binary signal curves (mapping species
activation levels to 0/off or 1/on) and compared them to
simulated initial I/O responses in M1 and M2 with strict
respect to experimental settings (see ‘‘Methods’’ for further
descriptions). We again concentrated on initial post-receptor
events and further assumed ‘‘general case’’ cellular signal
propagations by omitting all ‘‘t = 2’’ interactions.
87% of all tested species activation levels regarding
IL-1-associated treatment scenarios could be successfully
reproduced by M1. The additional omission of inhibitor-
dissociation processes initiated through MEKK3 activation,
alternatively contributing to IkBa release from transcription
factor NF-kB (as proposed by Yao et al.44), increased model
consistency to 88% (Fig. 6). One might therefore conclude
that IkBa inhibition is, at least in initially responding primary
human hepatocytes, predominantly mediated through degra-
dation, whereas dissociation seems negligible.
Simulation of IL-6-induced signalling events in M2 revealed
82% conformance of model predictions and discretised experi-
mental data, leaving inconsistencies primarily attributable to
p70S6K activation (9%) integrated via ITT gate expression
and thus provoking indeterminable states (cf. yellow entries
in Fig. 7). Again, conclusions with respect to model modifica-
tions are discussed below.
Interpretation of discrepancies between model predictions and
measured data and hepatocellular model optimisation
The detected inconsistencies between experimental data and
model predictions regarding the initial cellular response upon
interleukin and/or inhibitor treatment of hepatocytes revealed
suitable starting points for optimisation and specification of
the introduced ‘‘master models’’ with respect to hepatocytic
characteristics. Referring to the delineated discrepancies con-
cerning predicted and measured responses (Fig. 4–7), the
following model modifications, starting with model M1, were
introduced to improve consistency.
 Positive-regulatory influence of IKKb on Akt activity: the
yet missing but experimentally evident positive-regulatory
















































































This journal is c The Royal Society of Chemistry 2011 Mol. BioSyst., 2011, 7, 3253–3270 3259
and 15 (1;5/15) and column 1; line 5 (1;5) in Fig. 5) was
integrated indirectly by assuming ERK1/2-mediated p90RSK
activation, subsequent p90RSK- or directly ERK-regulated
Raptor (- mTORC1) activation,45,46 mTORC1-mediated
p70S6K activation,23,47 and up-regulation of catalytic Rictor
(- mTORC2) activity by p70S6K,48,49 the former being
directly involved in Akt activation.50 We therefore expanded
the IL-1-associated signalling network by three additional
species—mTORC1, p70S6K, and p90RSK—the latter two
seeming verifiably active upon IL-1 stimulation of primary
human hepatocytes.32
 Positive influence of JNK on MEK1 and ERK activity: to
reproduce the positive influence of JNK on MEK1 and ERK
activity (see (8;18/19) and (2;19) in Fig. 4 and (2;14) in Fig. 6),
we contemplate an alternative, redundant and IKKb-independent
(cf. (8;12) in Fig. 6) MEK1 activation mechanism via JNK
more significantly contributing to (apparently weak) ERK
than to MEK1 activation (see (8;14) in Fig. 6), though yet
Fig. 4 Comparison of interaction graph-based predictions and measured responses for various stimulus-response experiments with IL-1a in
primary hepatocytes. Measured effects on species activation levels for t= 30 min caused by different treatment scenarios (ligand and/or inhibitor)
in primary human hepatocytes (data published by Alexopoulos et al.32) were compared to predicted species dependencies within IG1 subject to
primary events. Each row represents the comparison of two experimental treatment scenarios (S1 and S2) to qualify corresponding effects
on network species (readouts) listed in the columns. Row labels are as follows: green (red) font colour indicates cytokine (inhibitor) application in
both scenarios S1 and S2. Up (down) arrows attached to species with black font colour mark cytokine (inhibitor) application in scenario S1,
implicating no cytokine or inhibitor addition in S2. For example, row 9 depicts the results when comparing S1 (IL-1a ligand + MEK1 inhibitor)
with S2 (IL-1a ligand), therefore showing effects of an increasing MEK1 inhibitor level in the presence of IL-1a on the readouts in the columns.
Matrix elements indicate structural (in-)consistencies according to the given colour legend. See ‘‘Methods’’ and Fig. S9.A (ESIw) for further
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lacking any biochemical confirmation. Generally, modifications
concerning IL-1-induced ERK activation are stated under
reserve, given measured ERK phosphorylation levels close to
or even beneath technical detection limits (see Fig. S9.A, ESIw),
partially impeding the falsification of already integrated inter-
actions (cf. (2; grey elements) in Fig. 4). A positive link between
JNK and MEK1/ERK activity would furthermore explain the
at least basally significant up-regulation of Akt by JNK (see
(1;18) in Fig. 4). Nevertheless and with respect to inconsis-
tencies apparent without additional IL-1 application (cf. row 18
in Fig. 4), unspecificity of the applied JNK inhibitor (Table S2,
ESIw) might qualify all given statements concerning additional
JNK involvement.
 Positive-regulatory influence of Akt on p38 MAPK activ-
ity: given the above mentioned suggestions for integration of an
‘IKKb- Akt’ and ‘JNK- ERK1/2’ (thus indirect ‘JNK-
Akt’) interdependence, the additional introduction of an alter-
native positive-regulatory influence of Akt on p38 MAPK
activity seems to be a convenient, though not yet documented
way to simultaneously cover the respective JNK, IKKb, and
PI3K involvement (see (9;13/15/19) in Fig. 4 and (9;14) in
Fig. 6). However, we suggest this with reservations, given the
abundance of discrepancies related to IL-1-induced p38 MAPK
regulation (cf. column 9 in Fig. 4), which might also point
to systematic uncertainties owing to marginal signal strengths
(Fig. S9.A, ESIw). Apart from that, cellular stress effects medi-
ated by p38 MAPK cannot be ruled out.
 Positive influence of p70S6K and basal effects of IKKb
on phospho-Hsp27-S78: IKKb appears to basally repress
Hsp27-S78 phosphorylation (see (4;14) in Fig. 4)—an effect
that might get superimposed upon IL-1 stimulation (cf. (4;15)
in Fig. 4) due to positive-regulatory p38/MK2 onset51 (corre-
lation already integrated) or alternative, direct p70S6K contribu-
tion. The latter, being activated in primary human hepatocytes
in response to IL-1,32 has been shown to act as a potential
Hsp27-S78 kinase in vivo.52 Introducing an additional
‘p70S6K- Hsp27-pS’ link would further facilitate the repro-
duction of p38-independent phospho-Hsp27-S78, apparent
despite p38 knock-down (see (4;10) in Fig. 6). Referring
to the logical inconsistency highlighted by (4;12) in Fig. 6,
one should note that IL-1 induces similar signal strengths for
t= 30 min concerning Hsp27-S78 phosphorylation regardless
of IKKb-inhibitor application (cf. Fig. S9.A (ESIw), right).
However, inhibitor-associated loss of suggested basal repres-
sion dramatically increases the phosphorylation level for t= 0
min, hence lowering the activating ‘‘net-effect’’ caused by
ligand add-on (see Fig. S9.A (ESIw), right) eventually used
for verification of logical implementations but not detectable
by the predefined parameter set in this special case (see (4;12)
in Fig. S12, ESIw). Due to ambivalences occurring when
additionally integrating inhibitory basal IKKb effects on
Hsp27-pS (Fig. 8), the latter were excluded during IG1 optimi-
sation, though maintaining the topological discrepancy (cf. (4;14)
in Fig. S11, ESIw).
 GSK3 inhibition: as the observed IL-1-induced effects on
GSK3-S9 phosphorylation (irrespective of inhibitor applica-
tion) range close to threshold parameters (see ‘‘Methods’’)
and are therefore not detected in the course of discretisation
(see (3;8) in Fig. 6), we do not speculate on alternative or
cooperative inhibitory GSK3 regulation mechanisms. None-
theless, studies by Ding et al.53 focusing on IGF-1- and
HBX-stimulated HepG2 or HepB3 cells, unveiled a positive-
regulatory influence of ERK-dependent p90RSK activity on
phospho-S GSK3, generally seeming more relevant in vivo
than a respective p70S6K contribution.54 Given that both
kinases, p90RSK and p70S6K, seem to be up-regulated in
response to IL-1 (see above), mentioned effects should be kept
in mind.
Fig. 5 Comparison of interaction graph-based predictions and measured responses for various stimulus-response experiments with IL-6 in
primary hepatocytes. See Fig. 4 for further explanations and colour legend. Predictions were made using IG2 subject to primary events. Respective
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Structural modifications covering the described interdepen-
dencies and summarised in Fig. 8 increased logical consistency
in M1 to 89% (Fig. S12, ESIw). Topological contradictions
with respect to IG1 underlying IL-1 signalling were reduced
to 3% (from 10%), though raising the percentage of experi-
mentally insignificant effects (grey entries) to 25% (from 12%)
and thereby lessening exact agreements to 72% (from 78%;
Fig. S11, ESIw). However, one should contemplate that, owing
to parallel pathways and saturation effects, signal transduction
along a positive path may not obligatorily lead to significant
up-regulation of its target species and is therefore not explicitly
quantifiable during measurements. This aspect might explain
the higher number of grey entries regarding the ‘‘optimised’’
IL-1 signalling network. Nonetheless, handling such marginal
cases a priori seems to be of secondary importance compared
to reducing the number of definitely falsified predictions
Fig. 7 Comparison of measured responses and predictions from the logical IL-6 model for various stimulus-response experiments with IL-6 in
primary hepatocytes. See Fig. 6 for further explanations and colour legend. Analysis was performed using the discretised activation levels depicted
in Fig. S10.B (ESIw) and model M2 subject to primary events. Yellow matrix elements outline model inconsistencies related to used ITT gate
expressions, the latter causing indeterminable states during simulation. Negative state: gsk3. Respective raw data are given in Fig. S10.A (ESIw).
Fig. 6 Comparison of measured responses and predictions from the logical IL-1 model for various stimulus-response experiments with IL-1a in
primary hepatocytes. Discretised activation levels (raw data assayed in primary human hepatocytes; cf. Alexopoulos et al.,32 Fig. S9.B (ESIw), and
‘‘Methods’’) for t= 30 min were checked against respective logical I/O responses computed using model M1 subject to primary events. Each row
refers to a particular treatment scenario (A + B) indicated on the left hand side. Respective readouts are given in the columns. Matrix elements
outline accordances or discrepancies between measured and predicted responses in keeping with colour legend. See text and ‘‘Methods’’ for further
information. Negative states: gsk3, ikba. Abbreviations: NO-LIG: no ligand/negative control; NO-INHIB: no inhibitor. Respective raw data are
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(red/orange entries in Fig. 4–7). Remaining discrepancies
(Fig. S12, ESIw) may give rise to additional clarifications
concerning the roles of PI3K or GSK3 in IL-1-induced ERK
or p38 MAPK activation, respectively (cf. (2;13) and (9;17)
in Fig. S11, ESIw), and considerations on a possible, basally
relevant positive effect of endogenous PI3K on IRS1-S phos-
phorylation (see (6;12) in Fig. S11, ESIw) in hepatocytes.
To quantify the overall improvement of the model we
introduce two simple error scores. The absolute error score
(Eabs) represents the total number of wrong predictions, i.e.
the number of red/orange entries in Fig. 4 (wrong interaction-
graph based predictions) plus those in Fig. 6 (wrong predictions
from the logical model). The relative error score (Erel) results
from the absolute error score divided by the total number
of predictions made. Regarding the original model M1, we
get EM1abs = 30 and E
M1
rel = 10.8% (with 277 predictions from
Fig. 4 and 6). With respect to network modifications shown in
Fig. 8, the optimised model M1 yields error scores of EM1optabs =
18 and EM1optrel = 6.5% (Fig. S11 and S12, ESIw) reflecting a
40% error reduction. These scores also enabled us to quantify
the relative contribution (or evidence) of the introduced network
changes. Taking the optimised model as a basis, we individually
removed each modificationm, recomputed EM1optmabs and defined
the increases in the number of wrong predictions, i.e. the
difference dm = E
M1optm
abs  EM1optabs , as the evidence level of
modification m. The evidence levels of all modifications in M1
are shown as (edge) weights in Fig. 8. For example, one can see
that modifications related to p90RSK, mTORC1, and p70S6K
had the strongest impact on model improvement. The intro-
duced edge from the reservoir variable ‘mtor’ to ‘mtorc2’ did
not affect the error score. However, ‘mtor’ was nonetheless
included to have a biologically reasonable description consis-
tent to that used within the IL-6 network.
Corrective modifications referring to IL-6 signalling (repre-
sented by model M2) were realised as follows.
 IL-6-induced p38 MAPK activation seems negligible in
hepatocytes, given indistinguishable effects of ligand application
on phosphoproteomic signal strength (see (6;1–6) in Fig. 5 and
(6;7–12) in Fig. 7; and Fig. S10.A (ESIw) depicting p38 MAPK
activation below detection limit (grey background)). Never-
theless, it has to be clarified how insignificantly up-regulated
p38 MAPK positively (though likely redundantly; cf. respective
entries in Fig. 7) contributes to ERK activation and inhibitory
GSK3-S phosphorylation (see (2;10) and (3;9/10) in Fig. 5) upon
IL-6 stimulation.
 ERK up-regulates p70S6K via mTORC1 activation/no
Akt involved: as already used to optimise the IL-1 signalling
network (see above), we imported the scenario (hitherto
undocumented for hepatocytes) delineated by Carriere et al.
whereupon ERK targets and phosphorylates the mTOR scaffold-
ing protein Raptor (- mTORC1) on several serine residues
either directly46 or via p90RSK activation,45 boosting its activity.
Fig. 8 Network modifications referring to initial IL-1 receptor signalling in primary human hepatocytes. See Fig. 1 and ‘‘Methods’’ for further
information on symbols etc. Species and interactions not directly affected as well as confidence levels are not depicted for reasons of clarity. Faint
components are adopted from master model representation with dashed arrows outlining up-stream activation events (see Fig. 1). Newly
introduced effectors and reactions are coloured intensely. Interactions seeming negligible with respect to initial cellular response according to our
data analysis results are crossed out. Numbers at new/to be removed edges show the respective interaction’s level of evidence, i.e. the numerical
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Documented p90RSK activation by primary human hepato-
cytes in response to IL-632 may support this hypothesis. Accord-
ing to statements by Kim23 and Shi et al.,47 mTORC1 might
subsequently mediate p70S6K-S phosphorylation, highlighting
an Akt-independent activation mechanism. Re-emerging discre-
pancies regarding p70S6K regulation (see (7;8/11) in Fig. S14,
ESIw) seem rather attributable to yet missing, alternative
MEK1/mTORC1-independent pathways than to Akt exclusion,
given a possible Akt involvement by mTOR de-repression as
reviewed by Hay and Sonenberg 55—an effect that would again
support mTORC1 activation and therefore MEK1/mTORC1-
mediated p70S6K up-regulation. A positive-regulatory link
between p70S6K and mTORC2 (as adopted for hepatocellular
IL-1 signalling; see above and Fig. 8) in response to IL-6 has
not yet been taken into account, owing to non-existent hints
from data analysis concerning the associated positive influence
of mTORC1 on Akt activity (cf. (1;14) in Fig. S13, ESIw).
 IRS1-S phosphorylation by ERK vs. PKCd: missing
positive-regulatory influences of PI3K on ERK activity and
subsequent ERK-catalysed IRS1-S636/639 phosphorylation
(see (2;12) and (4;11/12) in Fig. 5) could be ascribed to the
signal amplifying and Gab1-associated positive feedback loop
(see above) described by Eulenfeld and Schaper.56 Referring
to studies in IL-6-treated HepG2 cells by Kim et al.,23 another
ERK-mediated IRS1-S phosphorylation scenario, supposing
p70S6K as the predominant executing kinase could be initially
ruled out, given no significant impact of mTORC1 inhibi-
tion on phospho-IRS1-S636/639, though on p70S6K activity
(cf. (4;13/14) and (7;13/14) in Fig. 5). Furthermore, MEK1
knock-down leading to reduced ERK activity seems sufficient
to block inhibitory IRS1-S phosphorylation upon IL-6 treat-
ment (see (4;8) in Fig. 7), hence revealing respective PKCd
influences to be secondary.
 p70S6K contributes to inhibitory GSK3-S phosphoryla-
tion: though challenged in vivo by Stambolic and Woodgett54
and ruled out regarding initial IL-1 signalling (see above),
the integration of additional p70S6K-catalysed (apart from
Akt-mediated) GSK3-S phosphorylation upon IL-6 treatment
removed MEK1- and mTORC1-associated inconsistencies
concerning GSK3 inhibition (see (3;7/8/14) in Fig. 5 and (3;8/11)
in Fig. 7) and might thus, also with respect to stronger ERK
activation in response to IL-6 than to IL-1 (cf. Fig. S9.A and
S10.A (ESIw), left), be relevant for hepatocytic IL-6 signalling.
Taking these changes (visualised in Fig. 9) into account, we
could increase the accuracy of the logical model M2 from 82%
to 98%, getting residual discrepancies in just 2% of simulated
scenarios attributable to pending add-ons concerning p70S6K
regulation (Fig. S14, ESIw). Topological accordance with
respect to IG2 increased to 84% (originally 80%), leaving
8% (11%) experimentally indiscernible effects (grey matrix
elements) and 8% (9%) mismatches (Fig. S13, ESIw), the latter
(i) stressing the relevance for initial integration of Gab1-mediated
positive-regulatory feedback events demonstrated by Eulenfeld
and Schaper56 (see respective entries of row 11 and 12 in Fig. S13,
ESIw), (ii) pointing to need for clarification regarding the role
of p38 MAPK in IL-6 signalling (cf. respective entries of row 9
and 10 in Fig. S13, ESIw), and (iii) highlighting alternative,
IL-6-induced ERK activation strategies somehow comprising
mTORC1 and GSK3 (see (2;14/16) in Fig. S13, ESIw).
Similarly as for M1, we quantified the overall improve-
ments of model M2 by the error scores introduced above.
The absolute number of errors decreased from EM2abs = 27 to
EM2optabs = 12 and relatively from E
M2
rel = 12,9% to E
M2opt
rel =
5.7% (cf. Fig. 5 and 7 vs. Fig. S13 and S14, ESIw). Thus, the
inaccuracy of the model was reduced by more than 50%. The
individual evidence levels of the modifications (Fig. 9; for
definition see above) indicate that, analogously to the IL-1
network, the introduced pathway from p90RSK via mTORC1
to p70S6K had the strongest effect on model improvement.
Regarding stated model modifications, it should be pointed
out that many regulatory events, though a priori regarded
directly, may also reflect indirect effects transduced via several
Fig. 9 Network modifications referring to initial IL-6 receptor signalling in primary human hepatocytes. See Fig. 8 and 2 for further explanations.
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effectors and frequently additive mechanisms (e.g. de-repression
vs. catalytic activation) finally causing the observed ‘‘overall
effects’’.
Sensitivity of model predictions with respect to discretisation
parameters
To compare quantitative measurements with discrete predic-
tions from our models we had to discretise the experimental
data via four thresholds (one for detecting significant signal
changes; three for distinguishing active from inactive states;
see ‘‘Methods’’). To estimate the sensitivity of the obtained
results (i.e. the agreements and discrepancies in Fig. 4–7) with
respect to the relevant discretisation parameters, we computed
the relative number of (colour) changes in Fig. 4–7 resulting
when (a) decreasing and (b) increasing all thresholds by 10%
(note that the detection limit p3 = 500, representing a device-
dependent parameter, was not changed). For IL-1, 6.5%
(5.8%) of the entries in Fig. 4 and 6 changed colour with
threshold decrease (increase); concerning IL-6 we got 8.1%
(6.1%) colour changes in Fig. 5 and 7. This reflects a reason-
able robustness of the results which is further supported by
the fact that most changes concern green-to-grey or grey-to-
green transitions in Fig. 4 and 5 (only few of the critical
red/orange entries would disappear or newly appear). How-
ever, some discretised data points might range close to the edge
between significant/non-significant effects or active/inactive
states, respectively.
Relative network coverage with respect to perturbations and
readouts
A final issue to be discussed in conjunction with the network-
based data analysis is the coverage of the two networks with
respect to (i) perturbations (i.e. how many nodes are affected
by the inhibitors/cytokines) and (ii) readouts (i.e. how many
nodes are directly or indirectly measured by the readouts). In
order to quantify these two types of coverage, we computed
for each node n (separately for each model) how many of the
used stimuli (IL-1/IL-6) and inhibitors (mek1i, p38i, pi3ki,
mtorci, gsk3i, ikkbi, jnki; cf. Tables S1 and S2, ESIw) had an
influence on it (this number is denoted by sn) and how many of
the readouts are affected by it (and do thus at least partially
reflect the state of n; this number is denoted by rn). Hence,
sn quantifies controllability and rn observability of node n. One
cytokine and 6 inhibitors were used for perturbing the IL-1
network with its 97 nodes giving a maximal value of 7 for sn
whereas the maximal number for rn is 9 (total number of readouts).
Fig. S15.A and S16.A (ESIw) depict sn and rn for each node in the
IL-1 network for the primary (‘‘t = 1’’) events and Fig. 10
shows the resulting distributions of sn and rn. For 16 of the
network’s inputs we obviously got sn = 0 except for the
stimulus IL-1a itself. For the other species, at least one stimulus
reaches each node and some nodes are affected by five, six or
Fig. 10 Experimental coverage of modelled IL-1 receptor signalling.
A: Number of network species affected by each of the applied
cytokine/inhibitor treatments (stimulus). B: Distribution of numbers
of perturbations affecting IL-1 signalling species. C: Number of
network species affecting phosphoproteomic readouts. D: Distribution
of numbers of readouts affected by IL-1 signalling species. Corres-
ponding dependency matrices are shown in Fig. S15.A and S16.A
(ESIw). (Total number of IL-1-associated species: 97.)
Fig. 11 Experimental coverage of modelled IL-6 receptor signalling.
A: Number of network species affected by each of the applied
cytokine/inhibitor treatments (stimulus). B: Distribution of numbers
of perturbations affecting IL-6 signalling species. C: Number of net-
work species affecting phosphoproteomic readouts. D: Distribution of
numbers of readouts affected by species in the IL-6 signalling network.
Corresponding dependency matrices are shown in Fig. S15.B and
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even all seven stimuli. As expected, IL-1a influences the largest
set of species (>70) followed by the inhibitors ‘ikkbi’ (41) and
‘p38i’ (30). In contrast, ‘gski’ affects the state of only three
nodes as it is at ‘‘the bottom’’ of the network. Regarding the
observability levels (rn), we see a reduced coverage compared to
the perturbations. For 39 nodes no path connecting them with
any of the readouts exists. These species include in particular
transcription factors or ‘‘event nodes’’ (such as proliferation
or degradation of certain proteins) whose activity cannot be
reflected by the readouts (see Fig. 1). On the other hand,
7 nodes influence all 9 readouts and are thus well reflected in
the set of measurements. Concerning the readouts one sees
that ‘akt’ and ‘gsk3’ are influenced by the smallest set of
nodes (13 and 14, respectively) whereas the measurements of
‘irs1_ps’ (37), ‘ikba’ (35), and ‘erk12’ (34) are affected by a
large number of species.
The IL-6 network with its 75 nodes was perturbed by one
cytokine and five inhibitors implying a maximal value of 6
for sn whereas the maximum for rn (number of readouts) is 8.
Coverage analysis results with respect to early signalling events
are similar to those for IL-1 (see Fig. 11 and Fig. S15.B and
S16.B, ESIw). Except for the input nodes, all species are
directly or indirectly perturbed at least by the cytokine IL-6
and more than 50% of all nodes can be additionally affected
by one or more inhibitors. ‘pi3ki’ (20), ‘mtorci’ (19) and
‘mek1i’ (18) affect the largest number of nodes. Regarding
the observability coverage we see again that a considerable
number of (mainly output) species does not influence the
readouts. Their state can therefore not be captured by the
measurements. As 8 nodes affect all readouts, their state is well
reflected by the data. Measurements focusing on p70S6K and
GSK3 therefore appear to be most efficient for achieving a
high coverage of the IL-6 signalling network as they are
influenced by 28 and 24 nodes, respectively.
Generally, this type of coverage analysis seems useful to
examine the extent to which applied perturbation experiments
together with the available readouts are representative (i) for
the behaviour of the entire network and (ii) with respect to
certain species. In addition, it helps to identify most effective
perturbations and readouts.
Conclusion
By assembling current scientific knowledge on IL-1 and IL-6
signalling derived from various cell types, we reconstructed
two network models summarising IL-1- and IL-6-induced
signalling cascades. To the best of our knowledge, this has
not been conducted before at this scale. The logical approach
used for model set-up enabled us to convert simple relation
schemes to executable models. Though limited in reflecting
kinetic aspects, those Boolean representations are capable of
providing general and qualitative insights into global aspects
of signal propagation avoiding the need for detailed informa-
tion on kinetic mechanisms and parameters usually required
for quantitative (e.g. ODE-based) modelling. Topological
analysis revealed non-intuitive species interdependencies and
feedback structures e.g. demonstrating SHP2 and MKP1 to
be substantially involved in both negative and positive feed-
back loops. Qualitative I/O simulations revealing the initial
cell response upon ligand binding as well as the computation
of failure modes highlighted potential insulin-desensitising
effects and positive-regulatory contributions to HGF expres-
sion of both interleukins. This corroborates pathophysiologi-
cal links to insulin resistance and tumourigenesis in case
of chronic inflammation. Additionally, negative-regulatory
mechanisms, relevant for systemic ‘‘calming down’’ and stabili-
sation, seem to trigger IL-1-induced, though initially blocked
de novo IL-1 release due to suppression of inhibitory kinase
activities (e.g. inhibition of ERK by MKP1). Hence, negative
feedback loops impede autocrine effects but enable paracrine,
intercellular signal propagation indispensable for inflammatory
effector cell recruitment. Apart from that and as being a matter of
conjecture, visualised IL-1/IL-6 crosstalk-strategies (e.g. MK2-
regulated IL-6 receptor turnover or SOCS-mediated inhibition
of positive-regulatory TRAF6 ubiquitination) indicate mutual
and probably post-initial mechanisms to attenuate and thus
control the action of the respective inflammatory ‘‘fellow
player’’. The presented models fitted phosphoproteomic data
describing the initial response of primary human hepatocytes32
on interleukin treatment relatively well. Nevertheless, we could
also reveal some effects apparently specific to hepatocytes,
such as insignificant p38 MAPK activation but a markedly
involvement of the Gab1-mediated positive feedback loop
studied by Eulenfeld and Schaper56 during initial response to
IL-6 to name just a few. Moreover, subsequent hepatocellular
model specification suggested the integration of ERK-mediated
p90RSK activation and associated influences on mTORC1 and
p70S6K activity similarly induced by both ligands. In addition,
model verification pointed to hitherto undescribed IL-1-induced
positive regulation of p38 MAPK by Akt.
Taking the two structurally validated network models of IL-1
and IL-6 receptor signalling in hepatocytes presented here as a
basis, we plan to merge both networks in terms of crosstalk
scenarios and coinciding effectors (e.g.MAPKs, PI3K/Akt) and
direct our attention to further model falsification focusing
on cyclic, hence internally regulated and post-initial cellular
response. In order to do so, the explicit consideration of time
and signal strength will be necessary. ODEfy57,58 should in this
context be mentioned as a convenient approach for transform-
ing a given logical model into a corresponding set of qualitative
ODEs.57,58 The resulting dynamic model allows for ODE-based
simulations though with respect to and thus still reflecting
the logical relationships encoded in the Boolean model. Time-
resolved data may be used to identify required parameter sets
(which are significantly smaller than those for mechanistic
ODE models) completing the construction of the dynamic
model which then facilitates studies on essential properties of
the transient and quantitative behaviour of signalling cascades.
Our network models might therefore mark a suitable starting
point for set-up and analysis of ODE-based models.
The mentioned model transformation narrows the gap
between discrete and dynamic modelling frameworks, but, at
the same time, model complexity will rise in turn requiring
more detailed, at least semi-quantitative information on reac-
tion kinetics. Accordingly, detection of functionally coupled
species, forming so called equivalence classes introduced by
Samaga et al.30 and delineating regulatory motifs should be con-
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literature researches associated to manual model set-up in
mind, one should also contemplate software approaches auto-
mating Boolean model reconstruction and optimisation (e.g.
CellNetOptimizer59) via direct database access and incorpora-
tion of high-throughput data.
One important step in our future work is the integration of
the IL-1 and IL-6 network models. Herein we focused on
highlighting the mutual up- and down-regulation of IL-1 and
IL-6 signalling owing to transcriptional regulation and regu-
latory kinase/phosphatase onset but did not yet consider direct
crosstalks. In principle, one could easily merge the two network
models and tag common nodes. However, difficulties arise when
formulating the Boolean functions for common nodes where
IL-1- and IL-6-induced pathways converge. This type of infor-
mation is rarely available severely hampering the construction of
such an integrated logical model. Only the combined experi-
mental perturbation of the IL-1 and the IL-6 network would
allow for identification of respective logical relationships.
Methods
Model set-up
Extensive literature and database (NCBI/PubMed, UniProtKB/
Swiss-Prot, PhosphoSitePlus) research provided the ‘‘status quo’’
regarding IL-1 and IL-6 signalling, irrespectively of a certain cell
type, ensuring a biological starting point for setting up the logical
master models. In this context, especially the comprehensive IL-1
pathway map developed by Kracht et al.27,28 served as a helpful
overview.
Well-suited for formalisation, visualisation, and subsequent
qualitative analysis of signal transduction networks, usually
structured into input (encompassing e.g. cytokines, growth
factors), intermediate (e.g. kinases, phosphatases, scaffold
proteins) and output layer (e.g. transcription factors, gene
products), the Boolean networks studied within this work are
represented as logical interaction hypergraphs (LIHs) previously
introduced and utilised by Klamt et al.30,31,37 Accordingly, each
signalling species is denoted by a logical, herein solely binary,
state variable defining its discrete level of activation (0/off =
inactive or absent vs. 1/on = active or present). Associated
interspecific logical relationships are encoded by Boolean func-
tions exclusively using the logical operators AND (), OR (+),
and NOT (!) and complying with the sum-of-products (SOP)
notation.31,60 Within the models, each interaction/activation
event is expressed by means of AND-connected (potentially
negated) nodes (=species) triggering the event (activation of a
species) to be described. Hence, having several start nodes, they
represent hyperarcs in LIH representation.We keep on referring
to hyperarcs (or reactions/interactions) even if a reaction’s set of
start nodes comprises only one species (equivalent to a simple
arc in graphs). For effectors that might be influenced/activated
by various distinct events, i.e. by several hyperarcs (AND terms),
the latter are OR-connected and individually visualised bymultiple
hyperarcs pointing into the corresponding node. Considering the
scope of our model, certain signalling molecules serve as inputs
or side effectors, not being regulated by any network species. They
are therefore predefined by default values, reflecting basal acti-
vities, endogenous occurrences, catalytic indispensabilities, and
inhibitory functions. A special node type called reservoir serves to
link post-translationally modified proteins (e.g. ubiquitinated
scaffold proteins) to a common pool, enabling us to functionally
affect all subtypes by simply influencing the reservoir.
Examples supposed to clarify the LIH formalism as well as
its visualisation in Fig. 1 and 2 are listed in Table 1.
Occasionally, it is convenient to introduce accessory
‘‘dummy species’’, denoted by triangles in Fig. 1 and 2, to
express a logical relationship more efficiently (cf. line 6 in
Table 1).
In cases where an interaction could neither be fully approxi-
mated by using an AND nor an OR expression due to insuffi-
cient or inconsistent biological information we applied an
incomplete truth table (ITT) operator31 pointing at the ‘‘logical
overlap’’ of AND and OR operations (cf. line 7 in Table 1).
Affected species are activated/inactivated (1/0), if and only if all
positively influencing effectors are active/inactive (1/0), whereas
all negated input species are inactive/active (0/1). For all other
cases, the species’ state remains undefined.
Relevance and confidence level
Moreover, interactions are individually characterised by a
relevance level t, enabling the discrimination between primary
(t = 1) and secondary (t = 2) events (hence marking an
interaction to be relevant for the initial network response or
not). Primary events are considered to be active/available
during the initial cell response including gene expression,
whereas secondary events cover interactions (i) post-initially
closing feedback loops, (ii) initiating negative-regulatory
events that require the prior onset of species to be inhibited,
or (iii) being less relevant for the activation level of the target
species or outlining influences of catalytically aberrant enzyme
isoforms, respectively.
Removing secondary interactions with relevance level ‘‘t= 2’’
prior to computations enables us to focus on primary events
during simulations. Where required, the decoupling of secondary
‘‘t= 2’’ events from preceding AND gates (t= 1) is realised by
introduction of ‘‘timescale dummy species’’. These additional
nodes are not explicitly displayed in LIH representation but
italicised in corresponding SOP notation (cf. line 8 in Table 1).
According to Samaga et al.30 nodes within a feedback loop
having the shortest distance to the input layer are regarded as
associated initialisation points (z). Therefore, interactions
closing the cycle in node z are assigned t = 2.
Interactions are furthermore labelled (Table 2) by a confidence
level c, indicating the extent to which quoted citations under-
pin the respective effect in hepatocytes (cf. Fig. 1 and 2 and
Tables S3.2 and S4.2 (ESIw) of model documentations).
Complex AND gates were subjectively estimated with respect
to the individual confidence levels of interactions involved.
Model implementation was performed with ProMoT,33–35
providing the framework for model construction and visualisa-
tion subsequently exportable to CellNetAnalyzer (CNA)36,37
for model analysis as explained below. Generated results were
in turn re-imported to and graphically represented in ProMoT.
Mentioned software tools are freely available (for academic use)
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For detailed descriptions regarding the model configuration
(species, interactions, parameters) and related references see
supplementary model documentations (Tables S3.1–4.2, ESIw).
Topological analysis based on interaction graphs
By splitting all hyperarcs (AND connections) having more
than one start node into simple arcs, we deduced the respective
(signed and directed) interaction graphs (IGs)31 underlying the
logical models introduced here. Edges, entering an AND
connection in their negated form, are labelled by a negative,
otherwise by a positive sign. Arising duplicate arcs of the
same sign were removed to prevent redundancies. As shown by
Samaga et al.,30 IG analysis suits to studying topological
network properties, facilitating for instance the characterisa-
tion of feedback loops as well as identification of global species
interdependencies. The latter can be stored and visualised in
dependency matrices D.31
Logical network analysis: input–output behaviour and minimal
intervention sets
Using the logical models, we simulated the qualitative input–
output (I/O) behaviour of the signalling networks in response
to cytokine and/or inhibitor stimulation. In practice, input
signals are propagated along the logical links (=hyperarcs),
which is equivalent to computing the network’s logical
steady state (LSS) as described previously.30,31 Although
influencing cellular responsiveness and behaviour at longer
time scales, internal feedback loops may generally impede
LSS determination as described by Samaga et al.30 We there-
fore focused on the initial network response and excluded
secondary reactions (t = 2, see above), usually leading to an
acyclic network.
Another useful technique applicable to logical models are
minimal intervention sets (MIS).31 They are composed of
suitable species modifications or exogenous interventions (e.g.
constitutive activation or inhibition/knock-out) that enforce a
predefined cellular response (e.g. gene expression pattern or
phenotype) preferably of pharmacological interest. Restric-
tions regarding default values, relevance levels etc. can but
do not have to be taken into account. A detailed description on
the algorithm of MIS computation was given elsewhere.61
In this work, the MIS approach was applied to search for
Table 1 Examples illustrating the logical integration of biological relations and constraints
Biological statement Logical description
Visualisation in
Fig. 1 and 2
Species a autonomously activates/positively regulates species b a = b
Species a inhibits/negatively regulates species b !a = b
Species a AND b cooperatively activate/positively regulate
species c (hyperarc)
a  b = c
Species c gets activated/positively regulated, if species a
AND NOT b (e.g. inhibitor) function cooperatively
a  !b = c
Species a OR (b AND c) redundantly/alternatively activate/
positively regulate species d
a = d
b  c = d
Species a cooperates with species b OR c to activate species d a  b + a  c = d (SOP)) b + c = dum_b_or_c_d
) a  dum_b_or_c_d = d
a AND/OR b effect c in some way a * b = c
Species a AND b cooperatively activate/positively regulate
species c, subsequently counteracted/inhibited by species c
a  b  !c = c (t = 1) equals a  b  !tdum_c_c = c (t = 1),
whereas c = tdum_c_c (t = 2)
Table 2 Confidence levels and assignment criteria
Primary human hepatocytes,
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central regulatory mechanisms impeding uncontrolled cytokine
expression, cell proliferation, and viability.
Experimental data
We used high-throughput experimental data on primary human
hepatocytes published by Alexopoulos et al.,32 generated using
multiplexed bead-based ELISA type of assays (xMAP Technology
by Luminex, Austin/Texas), and checked for passage-to-passage,
preparation-to-preparation, and donor-to-donor variability. The
open access MATLAB-based software DataRail62,63 was utilised
for data management and visualisation. In brief and with regard to
species depicted by our models, the phosphorylation state of 11
intracellular signalling molecules was assayed at t= 0 and 30 min
(relative to cytokine addition) upon cell treatment with IL-1a or
IL-6 in combination with either none or one of 7 small molecule
kinase inhibitors (note that inhibitors were added 30 min prior to
cytokine application). For further information on experimental
procedures, cytokine and inhibitor concentrations, and data pro-
cessing see Alexopoulos et al.32 and Tables S1 and S2 (ESIw). The
selected data sets applied for validating the IL-1 and IL-6 model
are shown in Fig. S9.A and S10.A (ESIw).
Data analysis using interaction graphs
As delineated by Samaga et al.,30 we systematically compared
measured changes of a protein’s (p) phosphorylation state (xp)
assayed at t= 30 min due to differing treatment scenarios (e.g.
S1 = ligand (l) vs. S2 = ‘‘add nothing’’ or S1 = ligand (l) +
inhibitor (i) vs. S2 = inhibitor (i)) with respective IG-derived
predictions deduced from entries of the corresponding depen-
dency matrix (see ‘‘Topological analysis based on interaction
graphs’’). For this purpose, we focused on the ratio xp(S1)/x
p(S2),
quantifying the alteration of species phosphorylation caused by
the given stimulus scenarios. For example, in case of an increasing
signal owing to ligand application (xp(S1) > x
p(S2), i.e. x
p(S1)/
xp(S2) > 1), one would expect the existence of at least one direct
(edge) or indirect (path) positive regulatory influence of species l
on species p (l- p). Assuming structural consistence within the
associated IG, the respective entry of the dependency matrix Dl,p
(row l, column p) should point to an activating or ambivalent
influence. On the other hand, an increase (decrease) in species
phosphorylation while applying an inhibitor against associated
upstream effectors, suggests the presence of at least one negative
(positive) influence path from the inhibited protein (i) to p (i- p).
Thus, inhibitory effects could be treated analogously, considering
row i and column p of the dependency matrix. Differences in
signal strengths between S1 and S2 were taken as significant if
the larger signal exceeded the smaller one by at least 50 per cent at
t = 30 min, meaning:
xp(S1)/x
p(S2) Z 1.5 (signal increase in S1)
or
xp(S1)/x
p(S2) r 1/1.5 (signal decrease in S1) for t = 30 min.
Effects appearing beneath or close to technical detection limit
(xpr 500) were neglected. Moreover, we preassigned ‘‘negative
states’’ to signalling species whose activity is negatively regu-
lated by phosphorylation events (such as GSK3) and inverted
related dependency matrix elements accordingly. In consequence,
influences like the inhibition of a ‘‘negative’’ species p by ligand l
( ) as initially depicted by Dl,p would than be qualified as
positive regulatory events with respect to the measured inhibitory
phosphorylation.
Data analysis based on logical models
In strict accordance with experimental conditions, we further-
more compared measured data (activating vs. inhibitory species
phosphorylation) with simulated binary model predictions con-
cerning a species’ level of activation. The network’s I/O behaviour
was calculated as described above. Accordingly, default values
(see also ‘‘Model set-up’’) and other initial values reflecting the
presence/absence of ligands and/or inhibitors as prescribed by the
experimental set-up were fixed.
Inconsistencies between data and modelled I/O behaviour
may point to errors in the network structure. Following
Samaga et al.,30 raw data were discretised to binary values
prior to analysis ensuring their comparability with simulated
Boolean states. An effector (p) was considered ‘‘active or on’’,
if its phosphorylation status assayed at t= 30 min and caused
by a certain stimulus scenario S (xpS(t)) exceeded each of the
following thresholds (based on Samaga et al.30 with t0 refer-
ring to t = 0 min and max(xp) denoting the maximum signal




S(t0) Z 1.5 = p1. . . relative significance (signal
increase by at least 50% demanded),
xpS(t)/max(x
p) Z 0.15 = p2. . . absolute significance (at least
15% of the maximum level with respect to all measured
stimulus scenarios have to be reached), and
xpS(t) Z 500 = p3. . . lower detection limit.
Otherwise, the species was set to ‘‘inactive or off’’. Concern-
ing negative regulatory phosphorylation events and associated
‘‘negative states’’ (cf. ‘‘Data analysis using interaction graphs’’),
signals were discretised vice versa, saying xpS(t) = 0 if all
conditions specified above are true and xpS(t) = 1 elsewise.
In principle, the parameters defined above are regarded identical
for all signalling molecules studied here, proposing an analytical
starting point in want of reference values. Discretised data sets
are shown in Fig. S9.B and S10.B, ESI.w
Abbreviations (in bold) and molecule names
A20 zinc finger protein A20
ABIN2 A20-binding inhibitor of NF-kB 2
Akt protein kinase B (PKB)
AP-1 activator protein 1
APP acute-phase protein
C/EBP CCAAT/enhancer binding protein
CaMK II/IV Ca2+/calmodulin (CaM)-dependent protein
kinase II/IV
CCL2 chemokine (C-C-motif) ligand 2
CNA CellNetAnalyzer
CRP C-reactive protein
EGFR/ErbB epidermal growth factor receptor
ERK extracellular signal-regulated kinase
FL feedback loop
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gp130 glycoprotein 130
GSK3 glycogen synthase kinase 3
HGF hepatocyte growth factor
HNF4a hepatocyte nuclear factor 4 a




IKKb IkB kinase b
IL-1 interleukin 1
IL-1Ra IL-1 receptor antagonist
IL-1RII interleukin 1 receptor (IL-1R), type II
IL-6 interleukin 6
IL-8 interleukin 8
iNOS inducible nitric oxide synthase
IR insulin receptor
IRAK IL-1R-associated kinase
IRS1 insulin receptor substrate 1
ITT incomplete truth table
IkBa inhibitor of nuclear factor (NF) kB a
JNK c-Jun N-terminal kinase
LBP LPS (lipopolysaccharide) binding protein
LIH logical interaction hypergraph
LSS logical steady state
MAPK mitogen-activated protein kinase
MEK mitogen-activated ERK kinase
MEKK3 MAPK/ERK kinase kinase 3
MIS minimal intervention set
MK2 MAPK-activated protein kinase 2
MKP1 MAPK phosphatase 1
mTOR(C) mammalian target of rapamycin (complex)
MYD88 myeloid differentiation primary response gene 88
NEMO NF-kB essential modulator
NF-kB nuclear factor kB
ODE ordinary differential equation
p38 p38-mitogen activated protein kinase (MAPK)
p70S6K ribosomal protein S6 kinase, 70 kDa
p90RSK ribosomal protein S6 kinase, 90 kDa
PI3K phosphatidylinositol 30-kinase
PKCd protein kinase C d
RasGAP Ras (v-Ha-ras Harvey rat sarcoma viral onco-
gene homolog) GTPase activating protein
ROS reactive oxygen species
S serine
SAA serum amyloid A
SHP2 SH2 domain-containing protein tyrosine
phosphatase 2
sIL-1RAcP soluble IL-1R accessory protein
sIL-1RI/II soluble IL-1R, type I/II
SOCS suppressor of cytokine signalling
SOP sum of products
STAT signal transducer and activator of transcription
T threonine
TAB TGF (transforming growth factor) b-activated
kinase (TAK)-binding protein
TAK1 TGFb-activated kinase 1
TNF tumour necrosis factor
TPL2 proto-oncogene serine/threonine protein kinase
encoded by the tumour progression locus 2 (tpl2)
TRAF6 TNF receptor-associated factor 6
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